Cereno reports positive data from patient case study
Cereno Scientific has reported positive data received from a patient case study from the ongoing phase II trial with lead candidate CS1 in pulmonary arterial hypertension. The company’s CEO Sten R Sörensen passed by the BioStock Studio to comment on the significance of the results.
Watch the interview with Cereno‘s CEO Sten R Sörensen below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
